Akoya Biosciences, Inc.

Equities

AKYA

US00974H1041

Advanced Medical Equipment & Technology

Real-time Estimate Cboe BZX Other stock markets 07:27:42 18/06/2024 pm IST			5-day change	1st Jan Change
2.145 ^USD	+0.70%		-3.65%	-56.76%

03/06	Morgan Stanley Cuts Akoya Biosciences Price Target to $4 From $8, Maintains Overweight Rating	MT
15/05	Piper Sandler Cuts Akoya Biosciences Price Target to $6 From $8, Maintains Overweight Rating	MT

Akoya Biosciences, Inc. Provides Revenue Guidance for the Full Year 2024

May 14, 2024 at 01:30 am IST

Akoya Biosciences, Inc. provides revenue guidance for the full year 2024. For the year, the company is updating its revenue outlook for the full year 2024 while maintaining its commitment to achieving operating cash flow breakeven by year end. The Company now expects full year 2024 revenue to be in the range of $104.0 million to $112.0 million.

Latest news about Akoya Biosciences, Inc.

Morgan Stanley Cuts Akoya Biosciences Price Target to $4 From $8, Maintains Overweight Rating	03/06	MT
Piper Sandler Cuts Akoya Biosciences Price Target to $6 From $8, Maintains Overweight Rating	15/05	MT
Top Midday Decliners	14/05	MT
Top Premarket Decliners	14/05	MT
Exchange-Traded Funds Mixed, Equity Futures Higher Pre-Bell Tuesday Ahead of Powell Speech	14/05	MT
Akoya Biosciences Sinks Over 30% in Late-Hours Activity Monday as Q1 Sales Miss Capital IQ Estimate	14/05	MT
Transcript : Akoya Biosciences, Inc., Q1 2024 Earnings Call, May 13, 2024	14/05
Earnings Flash (AKYA) AKOYA BIOSCIENCES Reports Q1 Revenue $18.4M, vs. Street Est of $24.3M	14/05	MT
Akoya Biosciences, Inc. Provides Revenue Guidance for the Full Year 2024	14/05	CI
Akoya Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05	CI
Akoya Biosciences, Inc. and NeraCare Enters into an Exclusive Agreement to Enable Personalized Therapy Selection for Early-Stage Melanoma Patients	09/05	CI
Akoya Biosciences Opens Operations and Manufacturing Center of Excellence in Marlborough, Massachusetts	06/05	CI
Akoya Biosciences and Shanghai KR Pharmtech Announces Chinese Regulatory Agency Premarket Approval for KR-HT5 in China to Support Next Generation Pathology Clinical Workflows	02/05	CI
Akoya Biosciences Showcases Spatial Biology 2.0 Solutions At AACR Annual Meeting with Case Studies Demonstrating Unprecedented Speed and Scale	05/04	CI
JPMorgan Adjusts Price Target on Akoya Biosciences to $10 From $12, Maintains Overweight Rating	06/03	MT
UBS Adjusts Akoya Biosciences Price Target to $7.50 From $7, Maintains Buy Rating	05/03	MT
Akoya Biosciences, Inc. Provides Revenue Guidance for the Full Year 2024	05/03	CI
Transcript : Akoya Biosciences, Inc., Q4 2023 Earnings Call, Mar 04, 2024	05/03
Earnings Flash (AKYA) AKOYA BIOSCIENCES Posts Q4 Revenue $26.5M, vs. Street Est of $26.1M	05/03	MT
Akoya Biosciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	05/03	CI
North American Morning Briefing : Stock Futures -2-	04/03	DJ
Transcript : Akoya Biosciences, Inc. - Special Call	28/02
Transcript : Akoya Biosciences, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 03:45 PM	11/01
Akoya Biosciences, Inc. Announces Board Changes	11/01	CI
Akoya Biosciences Shares Jump on 2024 Outlook, Thermo Fisher Deal	09/01	DJ

Chart Akoya Biosciences, Inc.

Duration

Period

More charts

Company Profile

Akoya Biosciences, Inc. is a life sciences technology company delivering spatial biology solutions focused on transforming discovery, clinical research, and diagnostics. It offers single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. It offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhenoCode Panels and PhenoCycler, PhenoImager Fusion and PhenoImager HT Instruments. Its PhenoCycler platform provides ultra-high parameter biomarker discovery, with the ability to analyze high-plex single-cell resolution across the entire tissue sample. Its PhenoImager platform enables researchers to visualize, analyze, quantify and phenotype cells in situ, in fresh frozen or formalin-fixed paraffin-embedded (FFPE) tissue sections, and tissue microarrays (TMAs).

Sector

Advanced Medical Equipment & Technology

Calendar

05/08/2024 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Akoya Biosciences, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.13 USD

Average target price

6.143 USD

Spread / Average Target

+188.40%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
AKOYA BIOSCIENCES, INC.	-56.76%	105M
THERMO FISHER SCIENTIFIC	+7.71%	217B
DANAHER CORPORATION	+10.88%	188B
INTUITIVE SURGICAL, INC.	+28.37%	153B
BOSTON SCIENTIFIC CORPORATION	+31.17%	112B
SIEMENS HEALTHINEERS AG	-0.80%	62.84B
EDWARDS LIFESCIENCES CORPORATION	+14.14%	52.35B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+1.85%	49.33B
GE HEALTHCARE TECHNOLOGIES INC.	+1.03%	35.4B
RESMED, INC.	+22.92%	30.9B

Other Advanced Medical Equipment & Technology